In an era where drug-resistant infections pose a severe threat to global health, a groundbreaking approach emerges with a new class of antibiotics developed by Kinvard Bio.This innovative biotechnology startup, born from Harvard’s cutting-edge Myers Lab, aims to combat the escalating crisis of antibiotic resistance.